Home / Information / Lorlatinib
Lorlatinib
Lorlatinib is a 3rd generation TKI developed by Pfizer. The recommended dose is 100mg taken daily.
Currently, Lorlatinib has been approved by the NHS for use after Alectinib and Brigatinib in the UK. It has been approved by the Scottish Medicines Consortium for 1st line use in Scotland.
Documents
Name
Summary of Contents
Action
Managing Lorlatinib Together
NEW
An overview and practical guide for patients by ALK-positive patients and medical experts.
Management of Side Effects
NEW
A guide for health care professionals on the management of adverse effects arising from Lorlatinib.
Use of Lorlatinib with Paxlovid
NEW
Paxlovid is used to treat early Covid-19 infections. Here is Pfizer's statement about using it with Lorlatinib.
Crown Study 5-year Outcomes
This report contains information on the effectiveness of Lorlatinib for 1st line use.
Lorlatinib What to Expect (Pfizer)
A booklet from Pfizer on the side effects that patients may experience.
Weight Gain
Patients with weight gain of over 5% within 6 months developed significantly higher maximum gain
Lorlatinib - An Oncologist's Opinion
A discussion with Dr Camidge, a leading USA ALK+ expert.